3D7 Stock Overview A biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Willow Biosciences Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Willow Biosciences Historical stock prices Current Share Price CA$0.035 52 Week High CA$0.086 52 Week Low CA$0.035 Beta 1.12 1 Month Change -30.39% 3 Month Change -42.74% 1 Year Change -44.09% 3 Year Change -86.55% 5 Year Change -90.85% Change since IPO -97.16%
Recent News & Updates Willow Biosciences Inc. announced that it expects to receive CAD 2.001341 million in funding Nov 18
Third quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023) Nov 14
New major risk - Market cap size Sep 19
New major risk - Negative shareholders equity Aug 13
Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2023) Aug 13 Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024 Aug 13
See more updates Willow Biosciences Inc. announced that it expects to receive CAD 2.001341 million in funding Nov 18
Third quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023) Nov 14
New major risk - Market cap size Sep 19
New major risk - Negative shareholders equity Aug 13
Second quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2023) Aug 13 Willow Biosciences Inc. Provides Earnings Guidance for the Fiscal Year 2024 Aug 13
Willow Biosciences Inc. announced that it has received CAD 1.639737 million in funding Jul 18
Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024 Jun 08 Willow Biosciences Inc. announced that it expects to receive CAD 3 million in funding Jun 05
First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 1Q 2023) May 14
Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022) Mar 31
New minor risk - Shareholder dilution Mar 03 Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc. Feb 21
Third quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.032 loss in 3Q 2022) Nov 15 Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences Inc Oct 25
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding Oct 12
Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding Oct 11
Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding Sep 14
Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding Sep 13
Willow Biosciences Inc. Announces Successful Completion of R&D Program on Covid Sep 07
Willow Biosciences Inc. Announces Filing of Patent Application for Process to Produce Corticosteroids At Significantly Reduced Cost Aug 31
Willow Biosciences Inc. Announces Board Changes Aug 25
New major risk - Market cap size Aug 09
Willow Biosciences Inc. Announces Executive Changes May 13
Full year 2022 earnings released: CA$0.12 loss per share (vs CA$0.051 loss in FY 2021) Mar 22
Willow Biosciences Inc. Provides Earnings Guidance for the Year 2023 Dec 15
Insufficient new directors Nov 17
Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.031 profit in 3Q 2021) Nov 05 Willow Biosciences Inc. Appoints Dr. Peter Seufer-Wasserthal as its CEO
Willow Biosciences Inc. Completes Proof of Concept Work and Starts Yeast Strain Optimization and Process Development Toward Commercial Production of Astaxanthin Oct 13
Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.053 profit in 2Q 2021) Aug 16 Willow Biosciences Inc. Appoints Dr. Peter Seufer-Wasserthal as Interim President
First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.10 loss in 1Q 2021) May 15
Insufficient new directors Apr 27
Full year 2021 earnings released: CA$0.05 loss per share (vs CA$0.41 loss in FY 2020) Mar 31
Full year 2021 earnings released: CA$0.05 loss per share (vs CA$0.41 loss in FY 2020) Mar 31
Willow Biosciences Inc. Announces Results of its in Vitro Analysis and First to Report Topical Clinical Study on Cannabigerol in Collaboration with Signum Biosciences Jan 20
First quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.018 loss in 1Q 2020) May 09
Willow Biosciences Inc., Annual General Meeting, Apr 28, 2021 Feb 27
New 90-day high: €1.07 Feb 06
Willow Biosciences Inc. Advances its Work on Tetrahydrocannabinol and Plans to Launch in the Canadian Market Jan 20
Willow Biosciences Provides Update on Cannabigerol Research Studies Jan 14
New 90-day high: €0.84 Jan 14
New 90-day high: €0.51 Dec 22
Willow Biosciences Advances Its Commericalization Plan Dec 18
Willow Biosciences Inc. announced that it has received $1.168596 million in funding Nov 21
President recently bought €123k worth of stock Nov 01
Willow Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 10 million. Oct 30
New 90-day low: €0.34 Oct 30
Willow Biosciences Partners with Researchers At the University of Lethbridge and University of Calgary to Study Effects of Non-Psychoactive Cannabinoids on Pain, Inflammation and Depression Oct 10
Willow Biosciences Inc. Announces Successful Production of Pure Cannabigerol Sep 22
New 90-day high - €0.51 Aug 21
Earnings released Aug 13
New 90-day high - €0.35 Aug 04
Willow Biosciences to Commence Trading on The OTCQX® Best Market Jul 23 Shareholder Returns 3D7 DE Biotechs DE Market 7D -28.3% -2.6% -2.0% 1Y -44.1% -13.2% 6.8%
See full shareholder returns
Return vs Market: 3D7 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 3D7's price volatile compared to industry and market? 3D7 volatility 3D7 Average Weekly Movement 11.2% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 3D7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3D7's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.
Show more Willow Biosciences Inc. Fundamentals Summary How do Willow Biosciences's earnings and revenue compare to its market cap? 3D7 fundamental statistics Market cap €5.30m Earnings (TTM ) -€5.16m Revenue (TTM ) €1.92m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 3D7 income statement (TTM ) Revenue CA$2.87m Cost of Revenue CA$4.94m Gross Profit -CA$2.07m Other Expenses CA$5.65m Earnings -CA$7.71m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.054 Gross Margin -72.15% Net Profit Margin -268.91% Debt/Equity Ratio 361.0%
How did 3D7 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 19:23 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Willow Biosciences Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Kideckel ATB Capital Markets
Show 0 more analysts 
